Relationship between tumorsize of malignant pleural mesothelioma and its response to chemotherapy

被引:1
|
作者
Ozden, Hilmi [1 ]
Ak, Guntulu
Metintas, Selma
Metintas, Muzaffer
Sahin, Bunyamin
Erginel, Sinan
Civi, Kismet
机构
[1] Eskisehir Osmangazi Univ, Sch Med, Dept Anat, TR-26040 Meselik, Turkey
[2] Eskisehir Osmangazi Univ, Sch Med, Dept Chest Dis, TR-26040 Meselik, Turkey
[3] Eskisehir Osmangazi Univ, Sch Med, Dept Publ Hlth, TR-26040 Meselik, Turkey
[4] Ondokuz Mayis Univ, Sch Med, Dept Anat, TR-55010 Samsun, Turkey
[5] Dumlupinar Univ, Educ & Training Hosp, Dept Pathol, TR-43405 Kutahya, Turkey
关键词
Cavalieri principle; stereology; computed tomography; malignant mesothelioma; volume estimation;
D O I
10.1248/jhs.53.23
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Purpose: Malignant pleural mesothelioma (MPM) is an extremely lethal neoplasm and continues to be an important health problem in communities facing occupational or environmental exposure to asbestos. One of the most significant problems in the treatment of MPM is the lack of a standardized criterion for the evaluation of response to chemotherapy. In this study, differences between the tumor volumes of International Mesothelioma Interest Group (IMIG) stages, chemotherapy response, and patient response times were investigated. Patients and methods: We used the initial tumor volume determinations from patients with MPM with the point-counting technique indicated in the Cavalieri principle of stereologic design. Results: We observed reduction in tumor-volumes from tumor treatment until posttreatment. We found that those patients with the shortest period between initial diagnosis of a tumor volume of 200 mm(3) or greater had increases in volume of greater than 50 mm(3). Conclusion: There is still no standardized evaluation of MPM responses after chemotherapy to chemotherapy using classic criteria. However, our studies on tumor volume continuer.
引用
收藏
页码:23 / 30
页数:8
相关论文
共 50 条
  • [1] MicroRNAs Contribute to the Chemotherapy Response of Malignant Pleural Mesothelioma
    Kirschner, M.
    Zhang, Y.
    Schlapfer, F.
    Orlowski, V.
    Meerang, M.
    Opitz, I.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S898 - S898
  • [2] Chemotherapy for malignant pleural mesothelioma
    Vogelzang, Nicholas J.
    LANCET, 2008, 371 (9625): : 1640 - 1642
  • [3] Chemotherapy for Malignant Pleural Mesothelioma
    Garland, Linda L.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2011, 12 (02) : 181 - 188
  • [4] Chemotherapy for malignant pleural mesothelioma
    Tomek, S
    Manegold, C
    CURRENT OPINION IN ONCOLOGY, 2003, 15 (02) : 148 - 156
  • [5] Chemotherapy of malignant pleural mesothelioma
    Bertino, Pietro
    Carbone, Michele
    Pass, Harvey
    EXPERT OPINION ON PHARMACOTHERAPY, 2009, 10 (01) : 99 - 107
  • [6] Chemotherapy for Malignant Pleural Mesothelioma
    Linda L Garland
    Current Treatment Options in Oncology, 2011, 12 : 181 - 188
  • [7] Chemotherapy of malignant pleural mesothelioma
    Berghmans, T.
    Brechot, J. -M.
    Robinet, G.
    Guigay, J.
    Morere, P.
    REVUE DES MALADIES RESPIRATOIRES, 2006, 23 (04) : S57 - S70
  • [8] Response to chemotherapy of brain metastases from malignant pleural mesothelioma
    Colleoni, M
    Liessi, G
    Avventi, C
    Pancheri, F
    Sgarbossa, G
    Vicario, G
    Manente, P
    TUMORI, 1996, 82 (05) : 456 - 458
  • [9] Significant response to carboplatin/pemetrexed chemotherapy in malignant pleural mesothelioma
    Futtam, L.
    Carney, D.
    McCaffrey, J.
    LUNG CANCER, 2010, 67 : S20 - S20
  • [10] Pathological features of response to neoadjuvant chemotherapy in malignant pleural mesothelioma
    Sharkey, A.
    Le Quesne, J.
    Fennell, D.
    Nakas, A.
    Richards, C.
    Waller, D.
    Muller, S.
    VIRCHOWS ARCHIV, 2014, 465 : S373 - S373